Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
64Cu-DOTA Pembrolizumab PET in Oligo-Progressive Solid Tumors
NCT05728372Phase 1Withdrawn
- Sponsor
- City of Hope
- Start
- Aug 2023
- Primary completion
- Nov 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
01
Overview
Phase 1, open-label, single-arm trial of 64Cu-DOTA-pembrolizumab in malignant solid neoplasm, sponsored by City of Hope. Primary endpoints: Dose Limiting Toxicities at 1 month, Changes in 64CDP uptake at 6 weeks and 2 more. Planned start Aug 2023; status: withdrawn.
02
Drugs
64Cu-DOTA-pembrolizumab
03
Conditions
malignant solid neoplasm
Beyond the preview
Go deeper on NCT05728372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05728372.